A BRD9 specific degrader was developed as a tool compound to study the function of this bromodomain-containing protein [322], and it was demonstrated that degradation of BRD9 triggered downregulation of oncogenic programs that contribute to the development of synovial sarcoma/soft tissue tumors [81]. This evidence concerns the gene BRD9 and soft tissue neoplasm.